HANSHOW
28.2.2024 10:59:29 CET | Business Wire | Press release
Hanshow, a leader in retail technology innovation, today unveiled a series of Green Store Solutions, designed to accelerate the retail industry towards a sustainable future. Complementing this new product, Hanshow has also released a comprehensive Green Digitalization Report alongside tech partners Microsoft, Intel, and E Ink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223583112/en/
Hanshow at EuroCIS 2024 (Photo: Business Wire)
The Polaris Pro Electronic Shelf Labels (ESL) series stands out with its high screen-to-body ratio, multi-color display capabilities, and user-replaceable battery system designed for longevity, embodying Hanshow's commitment to sustainability. This advanced ESL solution is set to reduce paper waste, improve pricing accuracy, and enhance the overall aesthetic of modern retail environments.
Building on the innovative leadership of the Polaris Pro, Hanshow's Green Store Solutions extend beyond ESLs to include dynamic in-store marketing and AI-driven solutions. These innovations optimize store performance through targeted promotions, precise inventory management, and real-time data insights, facilitating smarter, greener operations.
To push the boundaries of what is possible in retail further, Hanshow integrates GenAI technology into its digital retail Solutions, enhancing operational efficiency and customer experiences. This adoption of GenAI simplifies complex processes and decision-making, making retail operations more efficient and intuitive. GenAI serves as an assistant to both store associates and customers, enabling easier navigation, personalized shopping experiences, and enhanced staff productivity.
Hanshow’s authoritative Green Digitalization Report, highlighting the dual benefits of digitalization and sustainability. The report, produced in cooperation with Microsoft, Intel, and E Ink, offers a deep dive into how retailers can use green digitalization as a double engine for growth, marrying eco-efficiency with cutting-edge innovation.
"Hanshow is proud to be at the forefront of the movement towards a greener, more digital future for retail," said Liangyan Li, SVP and Head of Global Sales at Hanshow. "With the introduction of the Polaris Pro series and our comprehensive Green Store Solutions, including our pioneering work on GenAI, we are paving the way for retailers to operate sustainably without compromising on customer satisfaction or operational excellence."
To further promote the many exciting ways in tech technology is laying a stronger foundation for sustainability in the retail industry, Hanshow’s Green Digitalization Report outlines actionable strategies to integrate sustainability into core business operations through innovative technologies. The report was released jointly with important contributions from industry partners such as Microsoft, Intel, and E Ink, and emphasizes myriad ways in which new technological advancements in AI, IOT, and data-driven decision-making will optimize management, reduce resource waste and store costs, improve associates’ work productivity and job satisfaction, and more accurately track and adjust customer experiences both in-store and online, all while helping retailers to meet sustainability targets.
Retailers eager to explore the Polaris Pro series, the suite of Green Store Solutions, and the findings of the Green Digitalization Report are invited to connect with Hanshow's team. Demonstrations and consultations are available to showcase how these initiatives can be seamlessly incorporated into existing retail frameworks.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223583112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom